Patients' Attitudes Toward and Experiences With Buprenorphine Treatment

Exploring the Attitudes and Experiences of Patients Engaged in Buprenorphine Treatment During the COVID-19 Pandemic

This study will disseminate five surveys collecting individual's attitudes and experiences during buprenorphine treatment for Opioid Use Disorder during the COVID-19 pandemic.

The primary objective of this study is to better understand patients' attitudes and experiences during office-based opioid treatment (OBOT) in the COVID-19 pandemic. This study specifically aims to evaluate attitudes and experiences of people prescribe buprenorphine across five domains with the hope of evaluating a) whether telemedicine has improved their access to and experiences with OBOT; b) the factors that motivate individuals in OBOT to abstain from opioid drug use; c) how patients' view the use of cannabis, benzodiazepines, and nicotine during OBOT; d) the degree to which patients in OBOT report using cannabis, benzodiazepines, and nicotine and how their use might have changed during the COVID-19 pandemic; and e) whether patients attitudes towards cannabis, benzodiazepines, and cigarettes/e-cigarettes are associated with their use of those same substances.

Inclusion Criteria:

• Participants must be 18 years of age or older.
• Participants report currently having a legal prescription for buprenorphine for opioid use disorder.
• Participants must have a past or present opioid use disorder.
• Participants must currently reside in the state of Massachusetts.
• Participants must be able to comprehend the English language.

Exclusion Criteria:

• Unable to complete an online survey.
• Unable to complete a verification step that ensures bots are not used to complete survey.
• Complete a survey with no variation suggesting they did not read the survey.